Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

about

Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid

P2860

Q38982212-1922923E-AF4A-4B9E-8463-170796C22C69

P2860

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

Item

http://www.wikidata.org/entity/Q37629416

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@en

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@nl

type

Item

label

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@en

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@nl

prefLabel

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@en

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@nl

P1476

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

@en

P2093

B G Murphy

http://www.w3.org/2001/XMLSchema#string

L A Tell

http://www.w3.org/2001/XMLSchema#string

S J McDonnel

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Histone deacetylase inhibitors in cancer therapy.

Histone deacetylase inhibitors and HIV latency.

Principles of treatment for feline lymphoma.

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

P304

196-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JVP.12088

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24236915

http://www.w3.org/2001/XMLSchema#string

P932

3949138

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

about

P2860

P2860

Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932